Unknown

Dataset Information

0

First-Row Transition 7-Oxo-5-phenyl-1,2,4-triazolo[1,5-a]pyrimidine Metal Complexes: Antiparasitic Activity and Release Studies.

ABSTRACT: Leishmaniasis and Chagas disease are still considered neglected illnesses due to the lack of investment in research, despite the fact that almost one million new cases are reported every year. Four 7-oxo-5-phenyl-1,2,4-triazolo[1,5-a]pyrimidine (HftpO) first-row transition complexes (Cu, Co, Ni, Zn) have been studied for the first time in vitro against five different species of Leishmania spp. (L. infantum, L. braziliensis, L. donovani, L. peruviana and L. mexicana) as well as Trypanosoma cruzi, showing higher efficacy than the reference commercial drugs. UV and luminescence properties were also evaluated. As a proof of concept, anchoring of a model high-effective-metal complex as an antiparasitic agent on silica nanoparticles was carried out for the first time, and drug-release behaviour was evaluated, assessing this new approach for drug vehiculation.

SUBMITTER: Martin-Montes A 

PROVIDER: S-EPMC10610057 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

First-Row Transition 7-Oxo-5-phenyl-1,2,4-triazolo[1,5-a]pyrimidine Metal Complexes: Antiparasitic Activity and Release Studies.

Martín-Montes Álvaro Á   Jimenez-Falcao Sandra S   Gómez-Ruiz Santiago S   Marín Clotilde C   Mendez-Arriaga José M JM  

Pharmaceuticals (Basel, Switzerland) 20230928 10

Leishmaniasis and Chagas disease are still considered neglected illnesses due to the lack of investment in research, despite the fact that almost one million new cases are reported every year. Four 7-oxo-5-phenyl-1,2,4-triazolo[1,5-a]pyrimidine (HftpO) first-row transition complexes (Cu, Co, Ni, Zn) have been studied for the first time in vitro against five different species of <i>Leishmania</i> spp. (<i>L. infantum</i>, <i>L. braziliensis</i>, <i>L. donovani</i>, <i>L. peruviana</i> and <i>L. m  ...[more]

Similar Datasets

Unknown 2-Phenyl-8,9,10,11-tetra-hydro-1-benzo-thieno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidine.
| S-EPMC3099952 | biostudies-literature
Unknown Ethyl 2-isopropyl-amino-6-methyl-8-oxo-3-phenyl-3H,8H-furo[2,3-d][1,2,4]triazolo[1,5-a]pyrimidine-7-carboxyl-ate.
| S-EPMC3007932 | biostudies-literature
Unknown Ethyl 5-chloro-methyl-2-methyl-sulfanyl-7-phenyl-4,7-dihydro-1,2,4-triazolo[1,5-a]pyrimidine-6-carboxyl-ate.
| S-EPMC2915003 | biostudies-literature
Unknown Bis(cyanato-κN)bis-(5,7-dimethyl-1,2,4-triazolo[1,5-a]pyrimidine-κN)zinc.
| S-EPMC3052141 | biostudies-literature
Unknown Crystal structure and Hirshfeld surface analysis of 5-methyl-1,2,4-triazolo[1,5-a]pyrimidine.
| S-EPMC6281126 | biostudies-literature
Unknown Ethyl 6-methyl-8-phenyl-1,2,4-triazolo[1,5-a]pyridine-7-carboxyl-ate.
| S-EPMC3885066 | biostudies-literature
Unknown 3-Methyl-4-(2-phenyl-1,2,4-triazolo[1,5-a]pyrimidin-7-yl)furazan.
| S-EPMC3884314 | biostudies-literature
Unknown Ethyl 5-methyl-7-phenyl-1,2,4-triazolo[4,3-a]pyrimidine-6-carboxyl-ate.
| S-EPMC4051068 | biostudies-literature
Unknown Synthesis and evaluation of 1,2,4-triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonists.
| S-EPMC2946083 | biostudies-literature
Unknown Factors Affecting the Stability of Platinum(II) Complexes with 1,2,4-Triazolo[1,5-a]pyrimidine Derivatives and Tetrahydrothiophene-1-Oxide or Diphenyl Sulfoxide.
| S-EPMC8998453 | biostudies-literature